Skip to Main Content

Paper Details

In vivo evaluation of the EZH2 inhibitor (EPZ011989) alone or in combination with standard of care cytotoxic agents against pediatric malignant rhabdoid tumor preclinical models-A report from the Pediatric Preclinical Testing Consortium.
Pediatr Blood Cancer
9
2021
EPZ011989, EPZ6438, EZH2, cyclophosphamide, irinotecan, pediatric malignant rhabdoid tumor, rhabdoid, rhabdoid models, rhabdoid tumors, tazemetostat, tumor, vincristine
Author NameAffiliation
Raushan T KurmashevaGreehey Children's Cancer Research Institute
Malcolm A SmithNational Cancer Institute
Malcolm A SmithNational Cancer Institute
Peter J HoughtonGreehey Children's Cancer Research Institute
  • 1 - 4

Datasets

Release 1.2